Guselkumab is safe and effective in patients with moderate-to-severe Crohn’s disease
1. The Guselkumab group demonstrated significantly greater clinical and endoscopic responses versus placebo. 2. Serious adverse events were comparable, with ...
Tag: ustekinumab
#VisualAbstract: Risankizumab was Non-Inferior to Ustekinumab for the Clinical Remission of Moderate-to-Severe Crohn’s Disease
Click here to read this study in the NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Risankizumab is superior to ustekinumab for endoscopic remission of Crohn’s disease
1. In this randomized controlled trial, risankizumab was non-inferior to ustekinumab in terms of clinical remission at 24 weeks in ...
Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease
1. Clinical remission at 52 weeks was similar between ustekinumab and adalimumab. 2. Patient-reported outcomes of stool frequency and abdominal ...
#VisualAbstract: Bimekizumab more efficacious than ustekinumab in treating severe plaque psoriasis
1. Bimekizumab showed higher efficacy in the treatment of severe plaque psoriasis than ustekinumab with patients showing greater proportion of ...
Bimekizumab shows better efficacy in treating severe plaque psoriasis than ustekinumab
1. Bimekizumab showed higher efficacy in the treatment of severe plaque psoriasis than ustekinumab with patients showing greater proportion of ...
